Axelar kicks off Phase I/II trial of brain tumor drug

01/22/2013 | Pharmaceutical Business Review Online

Swedish firm Axelar began a Phase I/II trial to assess the efficacy of its investigational drug, AXL1717, in patients with relapsed or progressive malignant astrocytomas. The oral insulin-like growth factor 1 receptor pathway inhibitor is also undergoing a midstage trial for nonsmall-cell lung cancer.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR